Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M. Trottier B, et al. Among authors: granier c. Antivir Ther. 2017;22(5):459-460. doi: 10.3851/IMP3192. Epub 2017 Sep 13. Antivir Ther. 2017. PMID: 28901945 No abstract available.
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators. Walmsley SL, et al. Among authors: granier c. N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541. N Engl J Med. 2013. PMID: 24195548 Free article. Clinical Trial.
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Walmsley S, et al. Among authors: granier c. J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790. J Acquir Immune Defic Syndr. 2015. PMID: 26262777 Free PMC article. Clinical Trial.
CD57+ EMRA CD8+ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy.
Gonnin C, Leemans M, Canoui-Poitrine F, Lebraud M, Corneau A, Roquebert L, Caillet P, Gay P, Canovas J, Histe A, Blanc C, El-Sissy C, Larbi A, Poisson J, Ober P, Boudou-Rouquette P, Natella PA, Vallet H, Saadaoui B, Layese R, Tartour E, Paillaud E, Granier C. Gonnin C, et al. Among authors: granier c. Immun Ageing. 2024 Dec 27;21(1):89. doi: 10.1186/s12979-024-00487-4. Immun Ageing. 2024. PMID: 39731117 Free PMC article.
Significant chlorine emissions from biomass burning affect the long-term atmospheric chemistry in Asia.
Chang D, Li Q, Wang Z, Dai J, Fu X, Guo J, Zhu L, Pu D, Cuevas CA, Fernandez RP, Wang W, Ge M, Fung JCH, Lau AKH, Granier C, Brasseur G, Pozzer A, Saiz-Lopez A, Song Y, Wang T. Chang D, et al. Among authors: granier c. Natl Sci Rev. 2024 Aug 16;11(9):nwae285. doi: 10.1093/nsr/nwae285. eCollection 2024 Sep. Natl Sci Rev. 2024. PMID: 39309413 Free PMC article.
328 results